Canngea Pty Ltd was incorporated in Sydney, Australia in 2017. Our mission is to bridge the gap between ancient and contemporary medicine for a better quality of life, and our vision is to be the leading medical cannabis manufacturer, storage and wholesale distributor in Australasia. Canngea sources and supplies: GMP approved white and private label formulation products; GACP & GMP dried flower products; Raw API materials (Active Pharmaceutical Ingredients) including THC distillates, biomass flower and CBD isolates. Canngea operates globally in partnership with S4 and S8 storage and distributors, manufacturers, cultivators and brand owners; as well as researchers and developers including the University of Sydney. We are committed to undertaking research and development (R&D) activities that can bring additional value to our business partners. We have a strategic partnership to facilitate R&D activities, through our Science Director Dr Nial Wheate with the School of Pharmacy at The University of Sydney, where Dr Wheate is also an Associate Professor. We are proud members of the leading industry associations Australian Medicinal Cannabis Association (AMCA) and API Manufacturers Association of Australia (APIMAA).